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Background: Platinum drugs, including cisplatin, are a frontline therapeutic in ovarian cancer treatment and
acquired resistance to these agents is a major contributor to ovarian cancer morbidity and mortality. In this study a
novel glycosylation-dependent mechanism for cisplatin resistance is described. Specifically, cisplatin-induced cell
death is blocked by the activity of the ST6Gal-I sialyltransferase. ST6Gal-I modifies specific receptors by adding a
negatively charged sialic acid sugar which influences diverse receptor functions. Overexpression of ST6Gal-I is a
hallmark of ovarian and other cancers and its expression has been correlated to metastasis and poor prognosis.
Methods: Tumor cell viability and apoptotic induction were determined in cell lines with ST6Gal-I overexpression
and knockdown. In addition, cell populations with acquired resistance to cisplatin were assayed for endogenous
ST6Gal-I expression.
Results: We show that forced expression of ST6Gal-I in OV4 ovarian cancer cells that lack endogenous ST6Gal-I
causes reduced activation of caspase 3 and increased cell viability following cisplatin treatment. Conversely, forced
ST6Gal-I knockdown in Pa-1 cells with high endogenous ST6Gal-I increases cisplatin-induced caspase activation and
cell death. A2780 ovarian cancer cells selected for stable cisplatin resistance display upregulated endogenous
ST6Gal-I when compared with parental, cisplatin-sensitive, A2780 cells. Similarly, extended low dose cisplatin
treatment of a Pa-1 polyclonal ST6Gal-I shRNA knockdown population led to selection for subclones with elevated
ST6Gal-I expression.
Conclusions: Receptor sialylation by ST6Gal-I confers a survival advantage for tumor cells in the presence of
cisplatin. These collective findings support a role for ST6Gal-I in chemoresistance and highlight ST6Gal-I as a
potential therapeutic target for platinum resistant tumors.
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The β-galactoside α2-6-sialyltransferase ST6Gal-I cata-
lyzes the addition of the negatively-charged sugar, sialic
acid, to the termini of N-linked glycans on selected cell
surface or secreted proteins as they transit through the
Golgi. ST6Gal-I elaborates an α2-6 linkage of sialic acid
to galactose, and this enzyme appears to be the primary
sialyltransferase responsible for this modification in
most tissues [1,2]. Depending on the specific substrate
targeted by ST6Gal-I, α2-6 sialylation can modulate* Correspondence: bellis@uab.edu
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reproduction in any medium, provided the orprotein conformation, oligomerization and/or receptor
internalization (reviewed in [3]). Another important
function of α2-6 sialylation is to negatively regulate
certain galectin-dependent cell responses [4]. Galectins
are lectins that bind galactose-containing glycans, and
the addition of α2-6 sialic acid to galactose impedes
the ability of most galectins to bind their targets [4].
Given that many glycoprotein receptors are held on the
cell surface through an interaction with the extracellular
galectin lattice [5-7], ST6Gal-I-mediated sialylation can
block glycoprotein binding to the lattice, causing receptor
internalization. Conversely, α2-6 sialylation enhances the
surface retention of other types of receptor glycoproteins
[8], albeit through mechanisms not well-defined. TheseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulating the complement of receptors on the cell sur-
face, in addition to modulating the function of distinct gly-
coproteins through effects on receptor conformation and/
or clustering.
ST6Gal-I is overexpressed in many different types of
cancers including ovarian, breast, and colon carcinoma
(reviewed in [3,4]), and ST6Gal-I upregulation is driven
by oncogenic ras [9,10]. Elevated expression of ST6Gal-I
has been correlated with a negative patient prognosis in
breast and colorectal cancers [11,12]. Cell culture studies
suggest that ST6Gal-I promotes cell migration and inva-
sion, at least in part through altering the sialylation and
function of the β1 integrin [13-15]. More recently
ST6Gal-I has also been identified as an inhibitor of sev-
eral cell death pathways. For example, one important
function of extracellular galectins is to induce apoptosis,
and this activity is blocked by ST6Gal-I mediated
sialylation of galectin substrates [16-18]. Additionally,
our group has shown that sialylation of the Fas and
TNFR1 death receptors by ST6Gal-I hinders apoptotic
signaling in response to their respective ligands, FasL
and TNFα [8,19]. Finally, ST6Gal-I activity is associated
with resistance to radiation treatment [20].
In view of ST6Gal-I’s upregulation in cancer, as well as
its emerging role as an inhibitor of cell death pathways,
we investigated whether ST6Gal-I activity could influ-
ence the sensitivity of tumor cells to cisplatin. Cisplatin
is the parent compound of the platinum family of che-
motherapeutics commonly used in frontline ovarian can-
cer treatment. Cisplatin and other platinum derivatives
(e.g., oxaliplatin, carboplatin) function by forming inter-
and intra-strand crosslinks in DNA, leading to an apop-
totic cell death. Resistance to platinum drugs represents
a major treatment challenge in ovarian and other can-
cers. The vast majority of ovarian cancer patients have
an initial response to platinum compounds, however up
to 75% of patients will relapse, with most exhibiting drug
resistant disease [21]. The molecular events underlying
resistance are complex, and it is likely that different
tumor cells exhibit different mechanisms, or combina-
tions of mechanisms, to escape cisplatin-induced apop-
tosis. At present, investigations into the mechanisms of
tumor cell resistance to platinum agents have focused
on drug import or export [22], cytosolic inactivation
(e.g. by glutathione and other antioxidants) [23], com-
pensatory DNA repair [24], and defects in apoptotic
signaling [25]. The activation of caspases following
DNA damage is important for cisplatin-induced cell
death, therefore factors impinging on caspase activity
can influence drug efficacy. As well, cisplatin may elicit
cytotoxicity through mechanisms independent of DNA
damage, as cisplatin is known to bind many molecules
other than DNA, and can also modulate cytoskeletalstructure [26]. In the current study we describe a new mech-
anism for cisplatin resistance involving α2-6 sialylation of
glycoproteins by the ST6Gal-I sialyltransferase.
Methods
Cell lines
The Pa-1 ovarian cancer cell line was purchased com-
mercially through ATCC (Manassas, VA). Pa-1 cells were
cultured and grown in Dulbecco’s eagle's minimal essen-
tial medium (DMEM) with 4.5 g glucose supplemented
with 10% fetal bovine serum (FBS)(Hyclone) and 1%
antibacterial/antimycotic solution containing penicillin,
streptomycin, and amphotericin B (Invitrogen). Pa-1
cells were previously found to express high endogenous
levels of ST6Gal-I [13]. To examine the effects of
ST6Gal-I expression on cell response to cisplatin treat-
ment a shRNA construct targeting ST6Gal-I as well as
an empty vector control were introduced via a lentiviral
vector (empty vector and shRNA-expressing lentiviral
particles were purchased from Sigma). Pa-1 empty vec-
tor (EV) and ST6Gal-I shRNA-mediated knockdown
(sh.ST6) lines are stable, polyclonal cell populations
initially selected by puromycin at a concentration of
10 μg/ml, and then maintained in 0.5 μg/ml puro-
mycin. The OV4 ovarian cancer cell line was a generous
gift from Dr. Timothy Eberlein (Harvard, Cambridge,
MA). OV4 cells were cultured and grown in Dulbecco's
modified Eagle's MEM/Ham's F-12 50:50 (DMEM/F12)
supplemented with 10% FBS and 1% antibiotic/antimycotic
solution. OV4 cells lack detectable endogenous ST6Gal-I
expression and we previously forced ST6Gal-I expression
and an empty vector control by lentiviral transduction
(MOI = 3) [13]. Stable, polyclonal populations were isolated
through puromycin selection. A2780ip2 and A2780cp20
cell lines were generous gifts from Dr. Anil Sood (MD An-
derson Cancer Center). Lines were maintained in RPMI
media (Cellgro) supplemented with 10% FBS and 1% anti-
biotic/antimycotic solution. A2780cp20 cells represent a
cisplatin-resistant derivative cell line of A2780ip2 created
by repeated cisplatin exposure as previously described [27].
Immunofluorescence imaging
Cells were seeded onto 4-well chamber microscope
slides (Beckin Dickinson) and allowed to adhere over-
night. Cells were washed and fixed in 4% paraformalde-
hyde for 10 minutes followed by permeabilization in 5%
Triton X-100 (in PBS) for 5 minutes. Cells were then in-
cubated overnight at 4°C or 3 hr at room temperature
with the ST6Gal-I antibody (polyclonal, R&D Systems,
catalog # AF5924) and 3 hr at room temperature with
anti-Golgi Matrix-130 (GM-130) (monoclonal, BD Trans-
duction Laboratories). Following incubation with primary
antibody, cells were washed and incubated with anti-goat
Alexa-Fluor 594-conjugated or anti-mouse Alexa-Fluor
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Chambers were removed and DAPI-containing mounting
solution, Vectamount (Vector Labs), was placed onto each
well. Coverslips were added and the slides visualized
under a Nikon Eclipe 80i fluorescence microscope fitted
with a Photometrics CoolSNAP camera (Roper Scientific).
Images were analyzed on NIS elements software. ST6Gal-
I co-localization with GM-130 was imaged by confocal
microscopy.
Western blot
Prior to lysis cells were grown in puromycin free media
for at least one day, passaged normally, and plated onto
6 well tissue culture plates (Fisher) at a density of 7.5 × 105
cells per well. Cells were allowed to adhere overnight and
then treated with cisplatin. Cells were lysed on ice in
50 mM Tris-HCl (pH 7.4) containing 1% Triton X-100,
and a protease inhibitor cocktail (Roche Applied Bio-
science). Cell lysate was kept on ice for 40 minutes
vortexing regularly or lysates were sonicated using a
sonicator model C-18 (Fisher). Protein concentrations of
the lysates were determined using a modified Bradford
Assay (Sigma). Proteins were then resolved by SDS-PAGE,
and transferred to polyvinylidene difluoride membranes.
Membranes were blocked with 5% nonfat dry milk in TBS
containing 0.1% Tween 20 (TBST). Primary antibodies
against ST6Gal-I (R&D Systems) or cleaved caspase-3
(Cell Signaling) were added to the membrane. Membranes
were then washed and incubated with horseradish
peroxidase-coupled secondary antibody (Amersham) and
visualized with Immobilon enhanced chemiluminscence
reagent (Millipore). Protein loading was evaluated by
immunoblotting for either β-tubulin or β-actin (Cell
Signaling).
Cell viability assay
Cells were plated in opaque-sided 96-well plates (Corning)
at a density of 104 cells per well in 75 μl of media and
allowed to adhere overnight. Cisplatin stock solutions
were made by dissolving solid cisplatin in distilled water
to a concentration of 2.5 mM and stored at 4°C with new
solutions made monthly. On the day of each experiment,
stock solutions were used to dilute cisplatin into media to
obtain the desired concentrations, and then cells were
grown in the cisplatin-containing media for 21 hours
(Pa-1) or 24 hours (OV4). Cell viability was evaluated
by determining ATP content using the CellGlo ATP
quantification kit (Promega) following the manufac-
turer’s protocol. Luminescence was measured on a
Synergy 2 plate reader (Biotek).
Cell selection with cisplatin
The polyclonal Pa-1 sh.ST6 population contains stable
clones with varying levels of ST6Gal-I knockdown. Twocell flasks were grown in parallel; one with DMEM
containing 10% FBS and 1% antibiotic/antimycotic solution
(control), and the other with this media supplemented with
1 μM cisplatin. After a 3-week interval, greater than 90% of
the cells grown in cisplatin-containing media had died,
whereas the control population proliferated over this inter-
val. At the end of the 3 week incubation in cisplatin, the
remaining viable cells were resuspended in 10% FBS/
DMEM lacking cisplatin, and cultures were expanded to
gain a sufficient number of cells for lysis and western blot
analysis.
Results
Forced overexpression of ST6Gal-I confers tumor cell
resistance to cisplatin-induced apoptosis
In order to evaluate the effects of receptor α2-6 sialylation
on tumor cell sensitivity to cisplatin, we utilized cell
models with engineered ST6Gal-I expression. OV4 ovar-
ian cancer cells have no detectable endogenous ST6Gal-I
[13]; we therefore generated a stable cell line with forced
ST6Gal-I expression. As shown in Figure 1A, the majority
of cells with forced ST6Gal-I expression (ST6) exhibited
high levels of immunostaining for ST6Gal-I, whereas none
of the parental (Par) or empty vector-transduced (EV)
cells were positive for ST6Gal-I. We confirmed forced
ST6Gal-I expression by immunoblotting (Figure 1B). The
pattern of staining was consistent with Golgi localization,
evidenced by ST6Gal-I co-localization with the known
Golgi protein, GM-130 (Figure 1C). The Golgi is the
expected subcellular compartment for ST6Gal-I, demon-
strating that ectopically expressed ST6Gal-I is correctly
localized.
Par, EV and ST6 cells were treated with increasing
doses of cisplatin and evaluated for cell viability by
measuring ATP content. The ST6 cells maintained cell
viability at higher cisplatin doses as compared with Par
or EV cells (Figure 2A), indicating that ST6Gal-I-
mediated sialylation protects against cell death. We
also evaluated activation of caspase 3, the principal exe-
cutioner caspase responsible for directing apoptosis. In
concordance with cell viability assays, ST6 cells have
decreased activation of caspase 3 as compared with Par
or EV cells.
Forced ST6Gal-I knockdown sensitizes tumor cells to
cisplatin-induced cell death
To further establish a role for ST6Gal-I in cisplatin sen-
sitivity, ST6Gal-I expression was repressed by shRNA in
Pa-1 ovarian cancer cells, a cell line with high endogen-
ous levels of ST6Gal-I [13]. Effective knockdown of
ST6Gal-I was confirmed by immunostaining and im-
munoblotting (Figure 3A and B). Golgi localization of
endogenous ST6Gal-I is demonstrated by co-staining


























Figure 2 Forced ST6Gal-I expression protects OV4 cells from cisplatin-induced cell death. (A) Compared with Par or EV cells, OV4 cells with
forced ST6Gal-I expression (ST6) exhibit attenuated cisplatin-induced cell death, as measured by ATP content. Means and S.E.M.s are shown for a
representative experiment, with three independent experiments performed, and each experiment performed in triplicate. (B) ST6 cells have









Figure 1 ST6Gal-I expression in OV4 ovarian cancer cells. OV4 cells that have no endogenous ST6Gal-I were stably transduced with either
empty vector or ST6Gal-I-expressing lentivirus. ST6Gal-I expression was confirmed by immunocytochemistry (A) and immunoblotting (B). ST6Gal-I
localization to the Golgi is shown by co-localization with the Golgi marker GM-130 in the ST6Gal-I forced expression line (C) Par = parental; EV =
empty vector; ST6 = cells with forced ST6Gal-I expression.
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Figure 3 ST6Gal-I knockdown in Pa-1 ovarian cancer cells. Pa-1 cells that have high endogenous ST6Gal-I were stably transduced with either
empty vector lentivirus, or virus expressing shRNA for ST6Gal-I. ST6Gal-I knockdown was confirmed by immunocytochemistry (A) and
immunoblotting (B). ST6Gal-I localization to the Golgi was confirmed by co-localization with the Golgi marker GM-130 in the empty vector
transduced line (C) Par = parental; EV = empty vector; sh.ST6 = cells stably expressing shRNA for ST6Gal-I.
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were exposed to increasing doses of cisplatin, and moni-
tored for cell viability. As shown in Figure 4A, ST6Gal-I
knockdown decreased the viability of Pa-1 cells, indicat-





















Figure 4 shRNA-mediated ST6Gal-I knockdown sensitizes Pa-1 cells to
knockdown (sh.ST6) are sensitized to cisplatin-induced cell death, as measu
experiment, with three independent experiments performed, and each exp
cleaved caspase-3 following cisplatin treatment as compared with Par cellsthese results, sh.ST6 cells displayed greater activation of
caspase 3 (Figure 4B).
While results shown in Figures 2 and 4 indicated that
ST6Gal-I directly regulates cell response to cisplatin, it




cisplatin-induced cell death. (A) Pa-1 cells with stable ST6Gal-I
red by ATP content. Means and S.E.M.s are shown for a representative




Figure 5 Cells that are resistant to cisplatin have upregulated
endogenous ST6Gal-I. (A) Pa-1 cells with ST6Gal-I knockdown
(sh.ST6) were exposed to cisplatin for 3 weeks, and the remaining
viable population (sh.ST6 cis-res) was expanded and immunoblotted
for ST6Gal-I. (B) Pa-1 cells with ST6Gal-I knockdown do not
upregulate ST6Gal-I expression following a 24-hr treatment with
cisplatin (sh.ST6 + cis). (C) Parental A2780 ovarian cancer cells (Par)
and a cisplatin-resistant derivative population (Cis-res) were
immunoblotted for endogenous ST6Gal-I.
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have an inherent resistance to cisplatin that is independ-
ent of ST6Gal-I function. This observation is consistent
with the extensive evidence indicating that tumor cells
become resistant through many different mechanisms.
Another factor to consider is that the efficacy of cell kill-
ing depends not only on the amount of cisplatin added
extracellularly, but also on the rate of cisplatin uptake as
well as intracellular metabolism of cisplatin. The intra-
cellular half-life of cisplatin within OV4 and Pa-1 cells
was not measured in the current study, therefore the re-
lationship between intracellular and total cisplatin for
the two cell lines is not known. Nonetheless, it is note-
worthy that manipulating ST6Gal-I expression in an in-
herently resistant cell line (OV4) is still effective in
regulating cisplatin response, supporting a causal role
for ST6Gal-I in cisplatin sensitivity.
Extended cisplatin treatment selects for ST6Gal-I
expressing cells
Given that ST6Gal-I is upregulated in many types of
cancer, including ovarian carcinoma [28], we hypothe-
sized that cells with high ST6Gal-I expression may have
a selective survival advantage. To address this hypoth-
esis, we exposed Pa-1 cells with ST6Gal-I knockdown to
prolonged low-dose cisplatin treatment. Notably, the Pa-
1 sh.ST6 cell line represents a polyclonal cell population,
and some variability in the degree of ST6Gal-I knock-
down is observed among individual clones (as seen in
Figure 3A). Pa-1 sh.ST6 cells were treated continuously
with cisplatin for 3 weeks, during which greater than
90% of the cells were killed. The remaining viable popula-
tion was then harvested, expanded, and immunoblotted
for ST6Gal-I. As shown in Figure 5A, the viable cells ex-
posed to cisplatin (sh.ST6 cis-res) had a higher level of
ST6Gal-I, suggesting that ST6Gal-I conferred a survival
benefit. To address the possibility that cisplatin may
have induced ST6Gal-I expression, sh.ST6 cells were
treated for 24 hours with the same dose of cisplatin
(sh.ST6 + cis), however no changes in ST6Gal-I were
observed (Figure 5B). These data suggest that the en-
hanced expression of ST6Gal-I in sh.ST6 cells treated
with cisplatin for 3 weeks was due to selection for
clones with higher ST6Gal-I, rather than induction of
gene expression.
If the response of differentially-sialylated tumor cells
to cisplatin treatment is indicative of a general protective
effect of ST6Gal-I in the presence of cisplatin, then it
would be expected that other cell models of cisplatin re-
sistance may exhibit elevated ST6Gal-I expression. Thus,
we immunoblotted for ST6Gal-I in the A2780 ovarian
carcinoma cell line and its stably cisplatin-resistant de-
rivative, A2780cp20 [27]. As shown in Figure 5C, a
marked increase in ST6Gal-I expression was observed inthe cisplatin-resistant A2780cp20 cells (Cis-res), provid-
ing further evidence of an association between ST6Gal-I
upregulation and chemoresistance.
Discussion
Despite the clear clinical significance of chemotherapy
resistance, a single mechanism of resistance has not yet
been established for all cases. The multifactorial nature
of tumor cell resistance to cisplatin leaves open the possi-
bility of novel mechanisms that remain undiscovered. In
this study we show that forced expression of ST6Gal-I
confers resistance to cisplatin, whereas ST6Gal-I knock-
down conversely sensitizes cells to cisplatin. Furthermore,
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upregulation in endogenous ST6Gal-I protein, suggesting
that increased receptor α2-6 sialylation may provide
tumor cells with a survival advantage. These findings illu-
minate a new mechanism for chemoresistance, and
underscore the importance of the cellular glycosylation
machinery in drug response. An aberrant glycan profile
was one of the earliest identified characteristics of a
cancer cell, and selective enrichment in α2-6 sialylation
(relative to α2-3 sialylation), is a common feature of
transformed cells [3]. It is also known that platinum drug-
resistant cells have abnormal glycosylation [29,30], and
studies spanning more than two decades indicate that cis-
platin treatment alters the sialic acid content of tumor
cells [31-33]. The link between these glycosylation
changes and ST6Gal-I is currently unclear, however the
inhibitory effect of ST6Gal-I on cisplatin-induced cell
death is likely driven by the activity of variantly-sialylated
surface receptors, given that ST6Gal-I modifies glycopro-
teins bound for the plasma membrane or secretion (and
not cytosolic proteins). Interestingly, tumors expressing
activating ras mutations [34] or ras overexpression [35]
are typically resistant to cisplatin, and ST6Gal-I is one of
the targets upregulated by ras signaling [9,10]. Further-
more, we recently reported that high ST6Gal-I expression
correlates with expression of the cancer stem cell markers
ALDH1 and CD133, suggesting that ST6Gal-I activity
may contribute to stem-like cell behaviors including
chemoresistance [36].
One predominant surface receptor known to modulate
cisplatin sensitivity is the Fas death receptor. Fas is acti-
vated by binding to FasL, which in turn causes receptor
internalization, formation of the Death Inducing Signal-
ing Complex (DISC), followed by activation of apoptotic
caspases. Caspase activation is also a critical downstream
event following cisplatin-induced DNA damage, and
cisplatin-resistant cells exhibit attenuated activation of
caspases 3, 8 and 9 [35]. Cisplatin is reported to cause
clustering and activation of the Fas receptor in a ligand
independent manner [36], as well as increased Fas ex-
pression [37-43]. Additionally, cisplatin stimulates the
aggregation of Fas into lipid rafts [44,45], which is cor-
respondingly important for Fas internalization and apop-
totic signaling [46]. In mice with subcutaneous tumors
formed from syngeneic Lewis lung carcinoma cells, one
intraperitoneal dose of cisplatin induced a dramatic in-
crease in Fas expression in the tumors, and also stim-
ulated tumor regression [43]. In this same study, the
anti-tumor effects of cisplatin were abrogated in mice de-
ficient in FasL. These results implicate cisplatin-induced
Fas upregulation in promoting tumor cell death [43],
and further suggest that in order to acquire cisplatin-
resistance, tumor cells may evolve mechanisms to dis-
able Fas signaling. Our prior studies demonstrated thatFas is a ST6Gal-I substrate, and that increased α2-6
sialylation of Fas functions to inhibit Fas receptor inter-
nalization and DISC formation [8], effectively shutting
off Fas apoptotic signaling. Hence, α2-6 sialylated Fas
isoforms could play a part in cisplatin resistance.
Another potential mechanism for ST6Gal-I-mediated
cisplatin-resistance may involve the differential sialylation
of one or more drug transporters. Many cisplatin-resistant
cell lines show reduced accumulation of cisplatin [47],
pointing to dysfunctions in cell surface transporters that
control either drug uptake or efflux. Defective glycosyla-
tion of ATP binding cassette (ABC) transporters has been
suggested to contribute to cancer development, and
possibly, chemoresistance [48]. Liang et al. reported
that in epidermoid carcinoma cells selected for resist-
ance to cisplatin, the MRP1 transporter (also known as
ABCC1) was aberrantly glycosylated, and this was as-
sociated with mislocalization to intracellular compart-
ments and reduced cell surface expression [29]. Similarly,
altered N-glycosylation of MRP1 and MRP4 was correlated
with cisplatin and oxaliplatin resistance in ovarian cancer
cells [49]. In this latter study, N-glycosylation defects were
linked to reduced levels of two glycosyltransferases: (i)
N-acetylglucosamine-1-phosphate transferase, gamma sub-
unit (GNPTG) and (ii) mannosyl (alpha-1,6)-glycoprotein
beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5) [49].
N-glycans are also known to be crucial for the stability of
the ABCG2 transporter in the endoplasmic reticulum
[30,50]. These findings indicate the importance of glycosyl-
ation in transporter function, and suggest that studies of
variant transporter sialylation may be a fruitful area for fu-
ture research.
Although the mechanisms underlying the effects of
ST6Gal-I activity on cisplatin sensitivity are not yet
understood, the current study adds to the body of litera-
ture implicating this enzyme as a major contributor to
tumor cell survival. In addition to conferring cisplatin
resistance, ST6Gal-I-mediated receptor sialylation blocks
apoptotic signaling by the Fas [8] and TNFR1 [19] death
receptors, and also inhibits galectin-induced cell death
[16-18]. Taken together, these results suggest that
ST6Gal-I may be a promising clinical target, and that in-
hibition of ST6Gal-I expression or activity could be
employed to sensitize tumor cells to platinum drugs, in-
creasing therapeutic efficacy.
Conclusions
We demonstrate that ST6Gal-I expression in ovarian
tumor cells confers resistance to cisplatin-mediated cell
death and that cell lines selected for resistance to cisplatin
strongly express ST6Gal-I. Hence, tumor cell expression
of ST6Gal-I possibly contributes to chemotherapy resist-
ance in a clinical setting. This finding points to the poten-
tial of targeting ST6Gal-I in ovarian cancer treatment and
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resistance.
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